Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1113-1122

  Yan, G ^a   Xu, Yingxin ^a   Zhao, Yunshan ^a   Li, Li ^a   Sun, Peiming ^a   Liu, Hailiang ^a   Fan, Qinghao ^a   Liang, Kai ^a   Liang, Wentao ^a   Sun, Huiwei ^a   Du, Xiaohui ^a   Li, Rong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CIK cell; E2F 1; Orthotopic rectal cancer

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; ONCOLYTIC ADENOVIRUS; TRANSCRIPTION FACTOR E2F1;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DRUG EFFICACY; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; MTT ASSAY; NONHUMAN; ORTHOTOPIC RECTAL CANCER; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; VIRAL GENE THERAPY; VIRUS PURIFICATION; WESTERN BLOTTING;

ADENOVIRIDAE; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; RECTAL NEOPLASMS;

EID: 84899120467     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1149-5     Document Type: Article

References (46)

1. Rullier E, Denost Q, Vendrely V, Rullier A, Laurent C. Low rectal cancer: classification and standardization of surgery. Dis Colon Rectum. 2013;56:560-7.
2. McKenzie SP, Barnes SL, Schwartz RW. An update on the surgical management of rectal cancer. Curr Surg. 2005;62:407-11. (Pubitemid 40862390)
3. Arrazubi V, Suarez J, Novas P, Perez-Hoyos MT, Vera R, Martinez DPP. Chemoradiation of rectal cancer. Minerva Chir. 2013;68:11-26.
4. Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, et al. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther. 2009;16:905-15.
5. Lanson NJ, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 2003;63:7936-41. (Pubitemid 37466730)
6. Gupta VK, Park JO, Kurihara T, Koons A, Mauceri HJ, Jaskowiak NT, et al. Selective gene expression using a df3/muc1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003;10:206-12. (Pubitemid 36204408)
7. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, Rezaei N, et al. Distinct expression patterns of the transcription factor e2f-1 in relation to tumour growth parameters in common human carcinomas. J Pathol. 2004;203:744-53. (Pubitemid 38961560)
8. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, et al. Transcription factor e2f-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol. 2002;198:142-56. (Pubitemid 35243872)
9. Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G. G1-s transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat. 1999;56:105-12. (Pubitemid 29494828)
10. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, et al. E2f-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev. 2000;9:395-401. (Pubitemid 30265783)
11. Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on e1a, the e2f-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 2003;63:1490-9. (Pubitemid 36373634)
12. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An e2f-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res. 2002;62:3438-47. (Pubitemid 34651390)
13. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, et al. Cg0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12:305-13. (Pubitemid 43166208)
14. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, et al. A first in human phase 1 study of cg0070, a gm-csf expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188:2391-7.
15. Crompton AM, Kirn DH. From onyx-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets. 2007;7:133-9. (Pubitemid 46348627)
16. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, et al. A hepatocellular carcinoma-specific adenovirus variant, cv890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001;61:6428-36. (Pubitemid 32783248)
17. Lavilla-Alonso S, Bauer MM, Abo-Ramadan U, Ristimaki A, Halavaara J, Desmond RA, et al. Macrophage metalloelastase (mme) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. Cancer Gene Ther. 2012;19:126-34.
18. Wang H, Wei F, Li H, Ji X, Li S, Chen X. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model. Int J Mol Med. 2013;31:377-85.
19. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
20. DeVita VJ, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366:2207-14.
21. Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase ii clinical study. Cancer Immunol Immunother. 2012;61:2125-33.
22. Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18:1751-9.
23. Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther. 2013;20:70-6.
24. Yang Z, Zhang Q, Xu K, Shan J, Shen J, Liu L, et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing il-12 induce enhanced antitumor activity in liver tumor model. PLoS One. 2012;7:e44802.
25. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721-33. (Pubitemid 29328216)
26. Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying mda-7/il-24. Acta Pharmacol Sin. 2009;30:467-77.
27. Du X, Jin R, Ning N, Li L, Wang Q, Liang W, et al. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep. 2012;28:1743-9.
28. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72:1853-64.
29. Donigan M, Norcross LS, Aversa J, Colon J, Smith J, Madero-Visbal R, et al. Novel murine model for colon cancer: non-operative transanal rectal injection. J Surg Res. 2009;154:299-303.
30. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med. 2006;12:1213-9. (Pubitemid 44527360)
31. Tsutsumi S, Kuwano H, Morinaga N, Shimura T, Asao T. Animal model of para-aortic lymph node metastasis. Cancer Lett. 2001;169:77-85. (Pubitemid 32532099)
32. Nettelbeck DM. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med (Berlin). 2008;86:363-77.
33. Stevaux O, Dyson NJ. A revised picture of the e2f transcriptional network and rb function. Curr Opin Cell Biol. 2002;14:684-91. (Pubitemid 35449380)
34. Harbour JW, Dean DC. The rb/e2f pathway: expanding roles and emerging paradigms. Genes Dev. 2000;14:2393-409.
35. Sherr CJ, McCormick F. The rb and p53 pathways in cancer. Cancer Cell. 2002;2:103-12. (Pubitemid 41039110)
36. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the e2f family in human gastrointestinal carcinomas. Int J Cancer. 1999;81:535-8. (Pubitemid 29203048)
37. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP, et al. E2f-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res. 2004;24:3041-7. (Pubitemid 39407184)
38. Palaiologou M, Koskinas J, Karanikolas M, Fatourou E, Tiniakos DG. E2f-1 is overexpressed and pro-apoptotic in human hepatocellular carcinoma. Virchows Arch. 2012;460:439-46.
39. Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, et al. A modified e2f-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. 2009;16:1441-51.
40. Hao H, Dong YB, Bowling MT, Zhou HS, McMasters KM. Alteration of gene expression in melanoma cells following combined treatment with e2f-1 and doxorubicin. Anticancer Res. 2006;26:1947-56. (Pubitemid 43989454)
41. Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev. 2010;21:127-34.
42. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008;8:1581-8.
43. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on cik cells: first report of the international registry on cik cells (ircc). J Cancer Res Clin Oncol. 2011;137:305-10.
44. Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009;11:1076-83.
45. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311:1780-4.
46. Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther. 2013;21:620-8.